Navigation Links
Michael J. Fox Foundation Joins Effort to Recruit 10,000 People With Parkinson's Disease to New Web-Based PD Research Community

Limited-time special offer will make 23andMe personal genetics service available to people with PD for $25 instead of standard $399

NEW YORK, March 12 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research, together with personal genetics company 23andMe of Mountain View, California, and The Parkinson's Institute and Clinical Center of Sunnyvale, California, announced a call for 10,000 people with Parkinson's disease to join an ambitious new research community. The goal of the community is to empower individuals with PD to proactively impact research in real time, potentially helping to speed early-stage scientific discoveries toward practical therapeutic relevance in treating Parkinson's disease.

The 23andMe Parkinson's Disease Community, conceived and led by 23andMe, is a novel attempt to leverage DNA technology, the Internet, and patient participation to enhance scientific understanding of Parkinson's disease and the field's ability to develop breakthrough treatments.

"Exploring the potential of a Web-based approach to patient engagement for research purposes is well-aligned with our Foundation's mission," said Katie Hood, CEO of The Michael J. Fox Foundation.

For the past year, the Foundation has been funding a partnership between 23andMe and the Parkinson's Institute and Clinical Center to develop Web-based tools and surveys to gather information from a community of PD patients in a scientifically meaningful way. That project is still in development. In the interest of ensuring that the surveys can be put to immediate use once they are ready, 23andMe and the Parkinson's Institute are now formally beginning the work of building the community.

To accelerate this community's growth, through March 22, 23andMe is sponsoring up to 10,000 people with Parkinson's to join the community for $25 instead of the usual $399. To be eligible for this discounted rate, individuals must have been diagnosed with Parkinson's by a physician, be willing to provide a saliva sample for genetic analysis, and agree to participate in online surveys about their experience with Parkinson's. Participants' data will be kept anonymous, but will contribute to a larger pool of data about the PD community that will inform various Parkinson's research efforts over time.

In addition, members will have full access to the 23andMe Personal Genome Service(TM), which includes detailed, personalized reports across many health conditions and traits, including PD. They will also have the opportunity to share their experiences directly with others in the 23andMe community who have Parkinson's or who carry genetic markers placing them at increased risk for developing the disease.

More information on joining the community -- including information on how people with Parkinson's can obtain a discount code to participate in the limited-time reduced rate of $25 -- is available at

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded nearly $140 million in research to date.

    Media Contact:
    Holly Barkhymer
    (212) 509-0995 x242

    Research Contact:
    Brian Fiske, PhD
    (212) 509-0995 x203

SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... It’s official: Tattoo ... tattoo — a number even greater among Millennials (a whopping one in three aged ... and more people who are dissatisfied with their ink. In fact, RealSelf , ...
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... in the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience ... are often catastrophic contributors to diseases of the diabetic foot. The American ...
(Date:12/1/2015)... ... 2015 , ... The importance of volumetric breast density assessment ... numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society of ... use of Volpara Solutions’ quantitative breast imaging software tools for providing breast imaging ...
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... LOS ANGELES , Dec. 1, 2015 ... and development company specializing in oncology, today announced that ... for the company,s pivotal global Phase 3 clinical trial ... sarcoma (STS). Enrollment was originally estimated to be completed in ... trial being conducted under a Special Protocol Assessment from ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics ... development company, announces it has filed an Investigational New ... Administration (FDA) for the Company,s lead fully human antibody ... FDA acceptance, MabVax plans to initiate the Phase I ... --> --> The planned Phase I ...
(Date:12/1/2015)... CHESTERBROOK, Pa. , Dec. 1, 2015 /PRNewswire/ ... leader, announced the launch of CareFront, a first-of-its-kind ... of patients diagnosed with cancer. Designed to be ... newly diagnosed cancer patients with resources for their ... costs. The program also offers tools to help ...
Breaking Medicine Technology: